NCCN Guidelines for Patients® | Mantle Cell Lymphoma

41 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 4 Treatment guide Stage I and limited stage II Guide 6. Second-line treatment Prior first-line treatment What are the options? Immunochemotherapy ± radiation therapy • Clinical trial • Radiation therapy • Drug treatment ◦◦ Bendamustine ± rituximab ◦◦ Bendamustine, bortezomib, and rituximab ◦◦ Bortezomib ± rituximab ◦◦ Cladribine + rituximab ◦◦ Ibrutinib ◦◦ Ibrutinib, lenalidomide, rituximab ◦◦ Lenalidomide ± rituximab ◦◦ Venetoclax Radiation therapy only • Clinical trial • Immunochemotherapy (see Guide 7 ) Guide 5. Follow-up care Type of care How often is this care needed? Medical history, physical exam, blood counts, lactate dehydrogenase, metabolic panel, imaging • Every 3–6 months for 5 years ◦◦ If normal, then repeat every year or when needed

RkJQdWJsaXNoZXIy MTE3MTE1